BSEC Clears Beximco Pharma Board Overhaul, Salman F Rahman Dropped From New Nine-Member Board

🏛 The Bangladesh Securities and Exchange Commission (BSEC) has approved the reconstitution of Beximco Pharmaceuticals'' board, excluding the company''s vice-chairman Salman F Rahman and ending a prolonged regulatory and legal dispute over the composition of the listed pharmaceutical maker''s leadership. The new nine-member board was cleared at a BSEC commission meeting on 29 September 2026.

📊 The new board will comprise three representatives of the Beximco Group, one director nominated by IFIC Bank PLC, four independent directors (including one woman), and the company''s managing director. The Beximco Group representatives on the new board are ASF Rahman (chairman and founder of the group), Osman Kaiser Chowdhury (currently a director of Beximco Pharma) and Iqbal Ahmed (the company''s managing director). The reshuffle marks the formal exit of Salman F Rahman — a co-founder and vice-chairman of Beximco Group — from the pharmaceutical subsidiary''s board.

🤝 Background to the dispute

Salman F Rahman has been in custody since his arrest following the political changeover in August 2024. He previously served as private industry and investment adviser to former prime minister Sheikh Hasina. Following the change of government, the BSEC appointed independent directors to Beximco''s three listed companies — Beximco Ltd, Beximco Pharmaceuticals and Shinepukur Ceramics — in early 2025. The companies subsequently challenged the appointments in court, creating a prolonged regulatory and legal deadlock.

In September 2026, Salman agreed to step down from the boards of the group''s listed companies, paving the way for their restructuring and helping resolve the dispute. The three companies separately informed the BSEC of his decision, allowing the regulator to move forward with approving reconstituted boards.

Under the arrangement approved on 29 September, Beximco Pharmaceuticals will withdraw a pending lawsuit challenging the regulator''s earlier decision to appoint independent directors. The BSEC will then withdraw two of its previous orders related to the dispute, according to the regulator. The compromise solution allows both sides to claim a measure of victory while clearing the way for Beximco Pharma to resume normal board operations.

👥 Beximco''s massive debt burden

The board restructuring comes as the conglomerate faces severe financial and operational difficulties that have cast a shadow over its entire business empire. According to a Bangladesh Bank report submitted to the High Court, Beximco Group had outstanding loans and liabilities of Tk 50,098 crore as of 30 November 2024. Of this, Tk 25,524 crore had been classified as defaulted.

Investigations by the Bangladesh Financial Intelligence Unit (BFIU) also found alleged irregularities in the group''s borrowing, including loans obtained through entities described as non-existent or paper companies. Some funds were allegedly channelled into capital-market share manipulation, according to the BFIU findings. Following the political changeover and Salman''s arrest, the group''s loans and assets came under scrutiny from the courts and Bangladesh Bank, with options including receivership and asset sales considered for loan recovery.

🌏 Operational impact on Beximco subsidiaries

The financial difficulties have also disrupted operations across Beximco Group''s subsidiaries:

• ⚠ Beximco Ltd: Has remained out of production amid raw-material shortages and loan defaults, with the company unable to import inputs or sustain operations at its manufacturing facilities.
• ⚠ Shinepukur Ceramics: Has been operating partially because of difficulties importing raw materials, with capacity utilisation significantly below historical levels.
• ✅ Beximco Pharmaceuticals: Has continued its operations despite the broader group distress, although the company remains exposed to the group''s overall financial difficulties through intra-group exposures and shared corporate functions.

💰 Why the board overhaul matters

The BSEC''s approval of the reconstituted Beximco Pharma board is significant for several reasons. First, it ends a regulatory and legal deadlock that had paralysed decision-making at one of Bangladesh''s largest listed pharmaceutical companies for nearly two years. With a new nine-member board in place — including four independent directors and an IFIC Bank nominee — the company can now move forward with strategic decisions, financial reporting and corporate governance practices that had been stalled during the dispute.

Second, the inclusion of an IFIC Bank nominee on the board reflects the bank''s exposure to Beximco Group''s debt. IFIC Bank, which has been a significant lender to the group, now has a direct say in the company''s governance and strategic direction — a meaningful step towards protecting the interests of creditor banks in a situation where the group''s defaulted loan burden exceeds Tk 25,500 crore.

Third, the four independent directors (including one woman) bring external oversight to a board that was previously dominated by Beximco Group insiders. The independent directors will play a critical role in ensuring that the company''s governance, risk management and audit functions meet the standards expected of a listed company — particularly one that is also listed on the Alternative Investment Market (AIM) of the London Stock Exchange.

🤝 London Stock Exchange AIM implications

Beximco Pharmaceuticals is also listed on the Alternative Investment Market (AIM) of the London Stock Exchange — a listing that gives the company access to international capital but also imposes additional governance and disclosure obligations. The company has said that appointments to the new board will remain subject to applicable AIM rules and due diligence requirements, signalling that the new directors will need to clear London Stock Exchange compliance checks before formally taking their seats.

This AIM listing is a double-edged sword for Beximco Pharma. On one hand, it gives the company international visibility and access to a broader investor base. On the other hand, it means that any governance lapses or financial irregularities at the broader group level can quickly translate into reputational damage and potential regulatory action in London. The new board''s ability to demonstrate robust governance and clean up the company''s balance sheet will be critical to maintaining its AIM listing and investor confidence.

👥 Broader implications for Bangladesh''s corporate governance

The Beximco Pharma board overhaul is being closely watched as a test case for corporate governance reform in Bangladesh. The country''s listed companies have historically had weak corporate governance standards, with controlling shareholders often dominating boards and minority shareholders having limited voice. The BSEC''s willingness to push through a reconstituted board that includes four independent directors and a creditor bank nominee signals a more activist approach by the regulator.

If the Beximco Pharma model — where the regulator effectively forces the exit of a controversial controlling shareholder and installs independent directors alongside creditor representation — proves successful, it could set a precedent for similar interventions at other distressed listed companies in Bangladesh. This would mark a significant shift in the country''s corporate governance landscape, where historically controlling shareholders have operated with relative impunity.

The BSEC''s approval of the new Beximco Pharma board also comes amid a broader crackdown on defaulting loans and corporate irregularities at large conglomerates. Bangladesh Bank''s aggressive push on loan recovery, the BFIU''s investigations into alleged paper-company borrowing, and the courts'' willingness to consider receivership and asset sales for distressed groups all point to a more rigorous approach to enforcing financial discipline on the country''s largest business houses.

For Beximco Pharmaceuticals specifically, the new board''s immediate priorities will include restoring normal operations, addressing the company''s exposure to group-level financial difficulties, and rebuilding investor confidence both in Dhaka and on the London Stock Exchange''s AIM market. With Salman F Rahman''s exit and a reconstituted governance structure in place, the company has an opportunity to write a new chapter — but the scale of the broader Beximco Group''s financial challenges means the path ahead will be far from easy.